e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Pulmonary circulation I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
RV/TLC ratio as an independent prognostic indicator in idiopathic pulmonary arterial hypertension (IPAH)
A. Kacprzak, M. Szturmowicz, M. Franczuk, A. Fijalkowska, M. Kurzyna, M. Wieteska, S. Wesolowski, A. Torbicki (Warsaw, Poland)
Source:
Annual Congress 2009 - Pulmonary circulation I
Session:
Pulmonary circulation I
Session type:
Thematic Poster Session
Number:
3913
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Kacprzak, M. Szturmowicz, M. Franczuk, A. Fijalkowska, M. Kurzyna, M. Wieteska, S. Wesolowski, A. Torbicki (Warsaw, Poland). RV/TLC ratio as an independent prognostic indicator in idiopathic pulmonary arterial hypertension (IPAH). Eur Respir J 2009; 34: Suppl. 53, 3913
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Verification of flow rate stability in high-flow nasal cannula devices
DLCO biological controls in clinical practice.
Related content which might interest you:
6MWD in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 464s
Year: 2003
Towards prognostic biomarkers in pulmonary arterial hypertension
Source: Eur Respir J 2012; 39: 799-801
Year: 2012
Evaluation of FVC/DLCO ratio as a predictor for pulmonary hypertension in patients with interstitial lung diseases
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
Is there a fixed relationship between the mean and systolic pulmonary artery pressures in idiopathic pulmonary arterial hypertension (IPAH) and proximal chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2009 - Pulmonary embolism
Year: 2009
Determinants and prognostic value of kidney disease in pulmonary arterial hypertension
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018
Change in right atrial minimal volume is a prognostic marker in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – From microimaging to functional evaluation of the lung
Year: 2016
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Haemodynamic correlation and prognostic value of ventricular mass index (VMI) in non-surgically treated chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Year: 2008
Prognostic significance of pulmonary arterial pressure in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018
Year: 2018
Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 427s
Year: 2006
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH)
vs
idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Ventilation-perfusion mismatch during different exercise modalities in idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2008 - Pulmonary mechanics and gas exchange
Year: 2008
Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation
Source: Eur Respir J 2005; 26: Suppl. 49, 560s
Year: 2005
NT-proBNP variation in stable pulmonary arterial hypertension patients.
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Prognostic value of right ventricular function in patients with severe pulmonary hypertension associated with respiratory disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Pulmonary vascular gradient: A predictor of prognosis in pulmonary hypertension due to left heart disease
Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept